DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this compound. Additional details are available on the vismodegib profile page.
Generic Entry Opportunity Date for 203388
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 203388
|Mechanism of Action||Smoothened Receptor Antagonists |
Suppliers and Packaging for NDA: 203388
Profile for product number 001
|Approval Date:||Jan 30, 2012||TE:||RLD:||Yes|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Nov 11, 2028||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Dec 15, 2028||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL|
Complete Access Available with Subscription